Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity RatioInvested Capital

Alterity Therapeutics (ATHE) Invested Capital (2016 - 2025)

Alterity Therapeutics has reported Invested Capital over the past 5 years, most recently at $9.7 million for Q2 2019.

  • For Q2 2019, Invested Capital fell 29.41% year-over-year to $9.7 million; the TTM value through Jun 2019 reached $9.7 million, down 29.41%, while the annual FY2019 figure was $9.7 million, 29.41% down from the prior year.
  • Invested Capital for Q2 2019 was $9.7 million at Alterity Therapeutics, down from $13.7 million in the prior quarter.
  • Over five years, Invested Capital peaked at $23.4 million in Q2 2016 and troughed at $9.33 in Q2 2015.
  • A 5-year average of $10.8 million and a median of $11.7 million in 2018 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: skyrocketed 251064207.88% in 2016 and later dropped 29.41% in 2019.
  • Year by year, Invested Capital stood at $424.62 in 2015, then soared by 5515921.33% to $23.4 million in 2016, then fell by 24.02% to $17.8 million in 2017, then decreased by 22.85% to $13.7 million in 2018, then dropped by 29.41% to $9.7 million in 2019.
  • Business Quant data shows Invested Capital for ATHE at $9.7 million in Q2 2019, $13.7 million in Q2 2018, and $17.8 million in Q2 2017.